These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 1324692)

  • 1. Two different sites of action for platelet activating factor and 1-O-alkyl-2-O-methyl-sn-glycero-3-phosphocholine on platelets and leukemic cells.
    Salari H; Dryden P; Howard S; Bittman R
    Biochem Cell Biol; 1992 Feb; 70(2):129-35. PubMed ID: 1324692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of protein kinase C by ether-linked lipids is not correlated with their antineoplastic activity on WEHI-3B and R6X-B15 cells.
    Salari H; Dryden P; Davenport R; Howard S; Jones K; Bittman R
    Biochim Biophys Acta; 1992 Feb; 1134(1):81-8. PubMed ID: 1543759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-O-hexadecyl-2-metoxy-glycero-3-phosphatidylcholine--a methoxy ether lipid inhibiting platelet activating factor-induced platelet aggregation and neutrophil oxidative metabolism.
    Le Blanc K; Samuelsson J; Brohult J; Berg A; Palmblad J
    Biochem Pharmacol; 1995 May; 49(11):1577-82. PubMed ID: 7786298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-activating factor (PAF) receptor antagonists inhibit arachidonic acid induced platelet aggregation in rabbit whole blood.
    Ammit AJ; O'Neill C
    Lipids; 1991 Dec; 26(12):1189-92. PubMed ID: 1668116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets.
    Suzuki M; Sugatani J; Ino M; Shimura M; Akiyama M; Yamazaki R; Suzuki Y; Miwa M
    Am J Physiol; 1998 Jan; 274(1):C47-57. PubMed ID: 9458712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and antineoplastic properties of ether-linked thioglycolipids.
    Guivisdalsky PN; Bittman R; Smith Z; Blank ML; Snyder F; Howard S; Salari H
    J Med Chem; 1990 Sep; 33(9):2614-21. PubMed ID: 2391700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and antineoplastic properties of an ether glycerophosphonocholine, and analog of ET-18-OCH3-GPC.
    Salari H; Howard S; Bittman R
    Biochem Biophys Res Commun; 1992 Sep; 187(2):603-8. PubMed ID: 1530618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
    Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the metabolism of platelet activating factor (PAF-acether) by three specific antagonists from Ginkgo biloba.
    Lamant V; Mauco G; Braquet P; Chap H; Douste-Blazy L
    Biochem Pharmacol; 1987 Sep; 36(17):2749-52. PubMed ID: 2820421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1-O-hexadecyl-2-O-methyl-sn-glycero-3-phosphocholine inhibits diacylglycerol kinase in WEHI-3B cells.
    Salari H; Low M; Howard S; Edin G; Bittman R
    Biochem Cell Biol; 1993; 71(1-2):36-42. PubMed ID: 8392354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific receptor sites for 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes.
    Hwang SB; Lee CS; Cheah MJ; Shen TY
    Biochemistry; 1983 Sep; 22(20):4756-63. PubMed ID: 6313047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of correlation between cytotoxicity of agonists and antagonists of platelet activating factor [paf-acether] in neoplastic cells and modulation of [3H]-paf-acether binding to platelets from humans in vitro.
    Berdel WE; Korth R; Reichert A; Houlihan WJ; Bicker U; Nomura H; Vogler WR; Benveniste J; Rastetter J
    Anticancer Res; 1987; 7(6):1181-7. PubMed ID: 3442414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of platelet-activating-factor production by incorporation of naturally occurring 1-O-alkylglycerols in phospholipids of human leukemic monocyte-like THP-1 cells.
    Hichami A; Duroudier V; Leblais V; Vernhet L; Le Goffic F; Ninio E; Legrand A
    Eur J Biochem; 1997 Dec; 250(2):242-8. PubMed ID: 9428670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAF-agonistic and -antagonistic behaviour of new synthetic ether phospholipids. I. Studies on blood platelets in vitro.
    Ostermann G; Hofmann B; Kertscher HP; Till U
    J Lipid Mediat; 1990; 2(1):21-31. PubMed ID: 1966804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
    Takehara S; Mikashima H; Muramoto Y; Terasawa M; Setoguchi M; Tahara T
    Prostaglandins; 1990 Dec; 40(6):571-83. PubMed ID: 1965554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The degradation of platelet-activating factor and related lipids: susceptibility to phospholipases C and D.
    Wilcox RW; Wykle RL; Schmitt JD; Daniel LW
    Lipids; 1987 Nov; 22(11):800-7. PubMed ID: 3444369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-Alkyl-1,4-dihydropyridines derivatives as specific PAF-acether antagonists.
    Sunkel CE; de Casa-Juana MF; Santos L; Gómez MM; Villarroya M; González-Morales MA; Priego JG; Ortega MP
    J Med Chem; 1990 Dec; 33(12):3205-10. PubMed ID: 2175357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies.
    Ortega MP; García MC; Gijón MA; de Casa-Juana MF; Priego JG; Sanchez Crespo M; Sunkel C
    J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic effects of ether lipids and derivatives in human nonneoplastic bone marrow cells and leukemic cells in vitro.
    Schick HD; Berdel WE; Fromm M; Fink U; Jehn U; Ulm K; Reichert A; Eibl H; Unger C; Rastetter J
    Lipids; 1987 Nov; 22(11):904-10. PubMed ID: 3444383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine: an analogue of platelet-activating factor with partial agonist activity.
    Grigoriadis G; Stewart AG
    Br J Pharmacol; 1991 Sep; 104(1):171-7. PubMed ID: 1664761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.